---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-022193"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:59:14.710101+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kodiak Sciences Q1 2023 net loss $70.8M; four Phase 3 readouts expected in Q3 2023

## Summary
- Cash position $421.2M; net loss $70.8M ($1.35/share) vs $95.7M ($1.83/share) Q1 2022.
- R&D expenses $56.5M (down from $76.2M) due to maturation of tarcocimab program and manufacturing timing.
- Topline data for GLEAM, GLIMMER, DAYLIGHT studies expected July 2023; GLOW study expected September 2023.
- BEACON Phase 3 study met primary endpoint in 2022; company plans single BLA for tarcocimab if successful.
- Phase 1 dosing started for KSI-501 bispecific antibody biopolymer conjugate in DME.

## SEC filing metadata
- accession: 0000950170-23-022193
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017023022193/0000950170-23-022193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017023022193/kod-20230515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-022193
- JSON: https://secwatch.observer/filing/0000950170-23-022193.json
- Plain text: https://secwatch.observer/filing/0000950170-23-022193.txt

## Key facts
- Earnings Releases
  Kodiak Sciences Inc. reported the quarter ended March 31, 2023 results: net income $70.8 million, EPS $1.35 per share.
  - Period: the quarter ended March 31, 2023
  - Net income: $70.8 million
  - EPS: $1.35 per share
  - Result: reported results
  source text: The net loss for the first quarter of 2023 was $70.8 million, or $1.35 per share on both a basic and diluted basis
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468748/000095017023022193/0000950170-23-022193-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.